SCHEMBL6225293

SCHEMBL6225293

CS(=O)(=O)OCCCCOc1ccc(S(=O)(=O)C2(C(=O)NOC3CCCCO3)CCOCC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 20/20 0.56
MMP2 P08253 19/20 0.56
MMP8 P22894 19/20 0.56
MMP9 P14780 13/20 0.55
MMP1 P03956 3/20 0.55
ADAM17 P78536 1/20 0.55
MMP3 P08254 4/20 0.47
MMP7 P09237 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6224271 0.99 MMP13 (0.55) MMP13MMP2MMP8MMP9MMP1
SCHEMBL6223521 0.85 MMP13 (0.54) MMP13MMP2MMP8MMP9MMP1
SCHEMBL6223522 0.85 MMP13 (0.54) MMP13MMP2MMP8MMP9MMP1
SCHEMBL8329108 0.84 MMP13 (0.52) MMP13MMP2MMP8MMP9MMP1
SCHEMBL6268548 0.84 MMP13 (0.49) MMP13MMP2MMP8MMP9MMP1
SCHEMBL8334721 0.82 MMP13 (0.50) MMP13MMP2MMP8MMP9MMP1
SCHEMBL8325431 0.82 MMP13 (0.47) MMP13MMP2MMP8MMP9MMP1
SCHEMBL5919374 0.81 MMP13 (0.48) MMP13MMP2MMP8MMP9MMP1
SCHEMBL8321971 0.79 MMP13 (0.46) MMP13MMP2MMP8MMP9MMP1
SCHEMBL6205603 0.79 MMP13 (0.49) MMP13MMP2MMP8MMP9MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562928-A1 AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2005-08-17 EP disclosed
US-20050101641-A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors PHARMACIA CORPORATION 2005-05-12 US disclosed
US-6890928-B2 Aromatic sulfone hydroxamic acids and their use as protease inhibitors PHARMACIA CORPORATION (US) 2005-05-10 US disclosed
US-20040110805-A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors PHARMACIA CORPORATION 2004-06-10 US disclosed
WO-2004043943-A1 AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-05-27 WO disclosed
US-6689794-B2 SUPPRESSING MATRIX METALLOPROTEINASE AND/OR AGGRECANASE ACTIVITY PHARMACIA CORPORATION 2004-02-10 US disclosed
US-20040024024-A1 Aromatic sulfone hydroxamates and their use as protease inhibitors PHARMACIA CORPORATION 2004-02-05 US disclosed
EP-1385836-A2 AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2004-02-04 EP disclosed
US-20040010019-A1 Aromatic sulfone hydroxamates and their use as protease inhibitors PHARMACIA CORPORATION 2004-01-15 US disclosed
WO-2002092588-A2 AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110805-A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors MMP1, MMP7, MMP3 MMP13 7/4885MMP2 9/4885MMP8 33/4885
US-20050101641-A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors MMP1, MMP3, MMP7 MMP13 8/4885MMP2 12/4885MMP8 31/4885
US-20040010019-A1 Aromatic sulfone hydroxamates and their use as protease inhibitors MMP1, MMP3, MMP7 MMP13 10/4885MMP2 7/4885MMP8 34/4885
US-20040024024-A1 Aromatic sulfone hydroxamates and their use as protease inhibitors MMP1, MMP3, MMP7 MMP13 10/4885MMP2 7/4885MMP8 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.